Drugs / Iron Isomaltoside
Iron Isomaltoside
Trials 19
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03013439 | Jan → Jun 2017 | iron deficiency anemia, iron metabolism disease | Pharmacosmos A/S | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05299411 | Apr 2023 → Mar 2025 | chemotherapy-induced toxicity, colon carcinoma | Korea University Guro Hospital | Unknown | No outcome recorded |
| Phase 35 trials · 3 met primary | ||||||
| Phase 3 | NCT06248749 | Feb 2024 → Dec 2028 expected | anemia | University of Saskatchewan | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT03957057 | Sep 2020 → Apr 2022 | deficiency anemia, iron deficiency anemia | University Medical Centre Ljubljana | Completed | No outcome recorded |
| Phase 3 | NCT03238911 | Oct 2017 → Jun 2018 | iron deficiency anemia | Pharmacosmos A/S | Completed | Met primary |
| Phase 3 | NCT02972294 | Mar 2017 → Sep 2021 | anemia, bone disorder | University Hospital, Angers | Terminated | Met primary |
| Phase 3 | NCT01145638 | Oct 2010 → Apr 2014 | chemotherapy-induced toxicity, neoplasm | Pharmacosmos A/S | Completed | Met primary |
| Phase 48 trials | ||||||
| Phase 4 | NCT06830941 | Feb 2025 → Feb 2027 expected | anemia | Xie Jingyuan, MD | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06350955 | May 2024 → Jun 2026 overdue | hypophosphatemia | Lucie Favre | Recruiting | No outcome recorded |
| Phase 4 | NCT05358509 | Mar 2021 → Dec 2023 | iron deficiency anemia | Thomas Jefferson University | Completed | No outcome recorded |
| Phase 4 | NCT04505514 | Aug 2020 → Oct 2022 | anemia | University of Malaya | Unknown | No outcome recorded |
| Phase 4 | NCT04346004 | Apr 2020 → Mar 2023 | aortic valve stenosis | Yonsei University | Unknown | No outcome recorded |
| Phase 4 | NCT03466983 | May 2018 → May 2020 | inflammatory bowel disease | Pharmacosmos A/S | Completed | No outcome recorded |
| Phase 4 | NCT03229954 | Aug 2017 → Apr 2019 | postgastrectomy syndrome | Yonsei University | Unknown | No outcome recorded |
| Phase 4 | NCT02632760 | Jul 2016 → Apr 2024 | anemia | Bayside Health | Completed | No outcome recorded |
| Phase not applicable4 trials · 1 met primary | ||||||
| — | NCT07236788 | Mar 2025 → Dec 2026 expected | iron deficiency anemia, obesity disorder | China-Japan Friendship Hospital | Recruiting | No outcome recorded |
| — | NCT03610230 | Feb 2019 → Mar 2021 | iron deficiency anemia | The University of Hong Kong | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT03470649 | Mar 2018 → Apr 2019 | anemia, arthropathy | Seoul National University Hospital | Completed | Met primary |
| — | NCT03094182 | Mar 2017 → Aug 2019 | — | Yonsei University | Unknown | No outcome recorded |
| Comparator or background therapy5 trials | ||||||
| Phase 0 | NCT04061655 Comparator | Sep 2019 → Jan 2020 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 2 | NCT04206228 Comparator | Jan 2020 → Feb 2022 | aortic valve stenosis, disorder of iron metabolism and transport | Oslo University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT03565354 Comparator | Jul 2018 → Jun 2020 | colorectal cancer, iron deficiency anemia | Prince of Wales Hospital, Shatin, Hong Kong | Completed | No outcome recorded |
| Phase 4 | NCT05804071 Comparator | Mar 2023 → Jan 2024 | iron deficiency anemia, iron metabolism disease | Qianfoshan Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02999217 Comparator | Oct 2016 → Oct 2017 | colorectal neoplasm, iron deficiency anemia | Kaunas University of Medicine | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 26 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Iron Isomaltoside | “2.1Intravenous iron supplement：Iron Isomaltoside Injection（5ml： 500mg，Wasserburger Arzneimittelwerk GmbH）,Intravenous iron supplement” NCT05804071 ↗23“Iron Sucrose, Iron Gluconate or Iron Isomaltoside (Treatment group A) versus No Iron Infusion treatment” NCT06248749 ↗ “ferric carboxymaltose 1000 mg or Iron isomaltoside 1000 mg given Intravenously” NCT02632760 ↗ “Drug: Iron isomaltoside” NCT06350955 ↗ |
| Known as | ferric derisomaltose | “OBJECTIVE: To compare risks of hypophosphatemia and effects on biomarkers of mineral and bone homeostasis of intravenous iron isomaltoside (now known as ferric derisomaltose)...” PMID 32016310 ↗ Feb 2020 |
| Known as | IIM | “The HiFIT study is a multicentre, 2×2 factorial, randomised, double-blinded, controlled trial evaluating the effect of iron isomaltoside (IIM) (20 mg/kg) vs placebo and of TXA...” PMID 33455926 ↗ Jan 2021 |
| Known as | Monofer | “Intravenous Iron-induced Hypophosphatemia in Patients With Roux-en-Y Gastric Bypass: a Single-blind, Randomized Clinical Trial Comparing Iron Isomaltoside (Monofer®) and Ferric...” NCT06350955 ↗7“The investigators examined the effect of intravenous iron isomaltoside (Monofer®) administration on postoperative anemia and transfusion requirements in patients undergoing...” NCT03470649 ↗ “Iron Isomaltoside 1000 (Monofer®) consists of iron with a tighter binding to its carbohydrate moiety with less free iron” NCT03610230 ↗ “Dose-escalation Trial of the Safety, Pharmacokinetics, and Pharmacodynamics of Iron Isomaltoside (Monofer®)” NCT03013439 ↗ “iron isomaltoside (Monofer, Monoferric) ferric gluconate (FG) iron sucrose (IS)” NCT06248749 ↗ “The drug, iron isomaltoside (Monofer), will be infused one single high dose” NCT03229954 ↗ “Drug: iron isomaltoside(Monofer®)” NCT03565354 ↗ “iron isomaltoside (Monofer®)” NCT03957057 ↗ |
| Known as | Monoferric | “iron isomaltoside (Monofer, Monoferric) ferric gluconate (FG) iron sucrose (IS)” NCT06248749 ↗ |
| Route | Intravenous | “Iron isomaltoside intravenously as bolus or infusion” NCT01145638 ↗ |